Loading…
StockAnalyzerLoading…
Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and New Zealand. The company offers pharma solutions in the therapeutic areas of anaemia, blood and solid tumors, dermatology, haematology, infectious diseases, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation. It also provides in vitro tests for the diagnosis of various diseases, such as cancer, diabetes, Covid-19, hepatitis, human papillomavirus, and others; diagnostic instruments; and digital health solutions. Roche Holding AG has a collaboration agreement with Excalipoint Therapeutics to evaluate EXP011 in DLL3-expressing solid tumors. The company was founded in 1896 and is based in Basel, Switzerland.
www.roche.com ↗| Dr. Severin Schwan Ph.D. | Executive Chairman | 58 | 9,109,991 CHF |
| Dr. Thomas Schinecker | Group Chief Executive Officer | 50 | 4,693,779 CHF |
| Dr. Alan Hippe | Chief Financial Officer | 58 | 4,981,689 CHF |
| Ms. Wafaa Mamilli | Chief Digital & Technology Officer | 58 | — |
| Dr. Bruno Eschli | Head of Investor Relations | — | — |
| Ms. Claudia Bockstiegel | General Counsel | 61 | — |
| Dr. Nina Schwab-Hautzinger | Head of Group Communications | 50 | — |
| Ms. Maria Cristina A. Wilbur | Chief People Officer | 58 | 3,544,276 CHF |
| Dr. Nicolas Dunant | Head of Group Media Relations | — | — |
| Mr. Boris L. Zaitra | Head of Corporate Business Development | 53 | — |
| Year | Buybacks | Dividends | Acquisitions |
|---|---|---|---|
| 2021 | 18,991 | — | — |
| 2022 | -0 | 7,446 | -0 |
| 2023 | — | 7,590 | -0 |
| 2024 | — | 7,650 | 2,836 |
| 2025 | — | 7,731 | 911 |
Shares outstanding since 2017: -3.9% 6.63 bn → 6.37 bn. Fewer shares — the company buys them back and each holder owns more.